New combo therapy aims to tackle Hard-to-Treat cancers

NCT ID NCT07157956

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combination helps slow cancer growth. About 318 participants will be enrolled across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CVL006 combined with chemotherapy (pemetrexed, carboplatin) or targeted drugs (SKB264, DS-8201, Enfortumab Vedotin)
What this could lead to
If successful, this could point toward new combination treatments for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase I/II) with a small number of participants, so safety and efficacy are not yet established. The combinations may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.